{"name":"Dimerix Bioscience Pty Ltd","slug":"dimerix-bioscience-pty-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Metabolic","slug":"metabolic","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"DMX-200","genericName":"DMX-200","slug":"dmx-200","indication":"Diabetic kidney disease","status":"phase_3"}]}],"pipeline":[{"name":"DMX-200","genericName":"DMX-200","slug":"dmx-200","phase":"phase_3","mechanism":"DMX-200 is a dual VEGF and Ang2 inhibitor that blocks angiogenesis and vascular destabilization to reduce tumor blood supply and improve vascular function.","indications":["Diabetic kidney disease","Diabetic retinopathy"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiqwJBVV95cUxOdEhIV3lPamJHbFNhMmFsZTJHXzRMTGtHZUs0dV9lRTVQV0VDQmUwVEdDc0hReDZzcDVmLS1ONTRZa2dYWWR6R0V0dW9kd0xkQl9Da3d4T3lDZU9nSFNYTi1KV1MzWTc4WFpPbFJzby0zdDVMenV0dnZoejZDaXZxcGo5LTBpUFFQRVlRMEZXRlBtOENVV1ppSmlZTmYwQldsQUZSSzJWeWFrcW5oeUp3ZkZmanlzZmxKVWlVSWV2WElpNGV3THNfM0xDaW1yM3oteFFEdDVtREVZaElvZE9LR0JhaTkzTi1sVnpCc1hlaW5seXZ1V1FFRW4tQVRMN1NUbzVqU3doYlJjNG1MUm5EaDJ3TDJtLTNqWmNuNzBWZXVMUE16Nzl5STBCWQ?oc=5","date":"2026-04-06","type":"pipeline","source":"GlobeNewswire","summary":"Idiopathic Membranous Nephropathy Market is Predicted to - GlobeNewswire","headline":"Idiopathic Membranous Nephropathy Market is Predicted to","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxNaXRJQWQwX3lYcXVHX01hc1JYV2UwWjduY0I4bW1RSExkdVRaUFF0ZHJmQ1d4WEJGMDFsbnNPRms0eklHYTJIS2hRRFFGQ1VhMjlaNm5jZG9ZQ2Q1MG9WUjl4UnY2UjZpRnRfdGVJUzU0cWlhZlhYS2NtMmZtc0ZHbHNEMkNfbUE5N1JrZlhFZkR0VzBYZ3Z1V3Jtbw?oc=5","date":"2025-08-19","type":"trial","source":"Yahoo Finance","summary":"Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Analysis Demonstrates 12+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - Yahoo Finance","headline":"Focal Segmental Glomerulosclerosis Clinical Trial Pipeline Analysis Demonstrates 12+ Key Companies at the Horizon Expect","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxQb3AxSTVYUGN5TlV4eVZwcy10eXplTERDOEQ3RVduNlh0V3FVMURHR3F3OTFMaVNtRWh0cW5PdDVycm4tZmUwaXhuWFQwUVZzUXlpd2hjZGZKOC1vWi1Hc3o3YXlQNkRsV2U4RW1uWEViUEdpUkNOcVNUeXlsS3Nic3dPLUhfMm9DVTdfOUhTTktyNlJGUV9QTjgxbnpTUQ?oc=5","date":"2025-05-01","type":"trial","source":"Fierce Biotech","summary":"Amicus pays Dimerix $30M for late-phase rare kidney disease drug - Fierce Biotech","headline":"Amicus pays Dimerix $30M for late-phase rare kidney disease drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxPRXNHQXJGcUJOdFp1bFdENFR3VzktVEx3ZFBSaF9RNEJVUEExb09CcmZVQmRxbGNrVFg5TDBjSDhRUnc4QmhjaW1xa1I2OW1RSUo3WXNpZzJNa2V6aDFJckc4eDhEVExfaS1lNi1jMFBjMk9Gb3F3NTl4R2hUZ1RuNTlra21QZw?oc=5","date":"2025-01-07","type":"deal","source":"The Pharma Letter","summary":"Dimerix enters deal with FUSO for DMX-200 Japan - The Pharma Letter","headline":"Dimerix enters deal with FUSO for DMX-200 Japan","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-01-10","type":"pipeline","source":"PR Newswire","summary":"Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companies - ACELYRIN, Genentech, ChemoCentryx, Travere Therapeutics, Boehringer Ingelhei","headline":"Focal Segmental Glomerulosclerosis Market to Observe Impressive Growth by 2032, Predicts DelveInsight | Leading Companie","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiWEFVX3lxTE5TM2p2Nlk4V01md0V5Rzl4ZmRnMl9MNTBLUUI1NzZJZjVZaXA3T21DdmtoOVJoVUd5dlZRdG9XOHg5TEpJZXZoT3pJZktsN1NrdGw5QnozanA?oc=5","date":"2020-01-29","type":"pipeline","source":"Stockhead","summary":"Dimerix (ASX:DXB) - Stockhead","headline":"Dimerix (ASX:DXB)","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}